as of 11-19-2026 2:39pm EST
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCHESTER HILLS |
| Market Cap: | 277.6M | IPO Year: | 2005 |
| Target Price: | $18.50 | AVG Volume (30 days): | 136.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.35 | EPS Growth: | 181.82 |
| 52 Week Low/High: | $7.29 - $15.47 | Next Earning Date: | 11-05-2026 |
| Revenue: | $143,436,000 | Revenue Growth: | 6.36% |
| Revenue Growth (this year): | 1.42% | Revenue Growth (next year): | 5.89% |
| P/E Ratio: | 41.63 | Index: | |
| Free Cash Flow: | 23.8M | FCF Growth: | -7.46% |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
+2.29%
$13.45
Act: +1.25%
5D
+12.12%
$14.74
20D
+14.74%
$15.09
2 infu-20260930xexx991earnin.htm
Document
Exhibit 99.1
InfuSystem Holdings, Inc.
3851 W. Hamlin Road
Rochester Hills, MI 48309
(248) 291-1210
Contact:
Barry Steele
Chief Financial Officer
(248) 260-2211
InfuSystem Announces Financial Results for
Third Quarter 2026
Investor Conference Call to be held on November 10, 2026 at 9:00 a.m. Eastern Time
Net Revenues of $37.6 million Representing a 3.0% Increase from the Prior Year
Net income of $3.2 million
Adjusted EBITDA (non-GAAP) of $9.4 million
Adjusted EBITDA (non-GAAP) margin expanded by 2% to 25%
Reaffirms Full-Year 2026 Guidance
Rochester Hills, Michigan, November 5, 2026 – InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2026.
2026 Third Quarter Overview:
•Net revenues totaled $37.6 million, an increase of 3.0% vs. prior year.
◦Patient Services net revenue was $25.8 million, an increase of 15% vs. prior year.
◦Device Solutions net revenue was $11.8 million, a decrease of 17% vs. prior year.
•Gross profit was $21.7 million, an increase of 4% vs. prior year.
•Gross margin was 58%, an increase of 1% vs. prior year.
•Net income was $3.2 million, or $0.15 per diluted share vs. prior year net income of $2.3 million, or $0.11 per diluted share.
•Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) (non-GAAP) was $9.4 million, an increase of 12% vs. prior year.
•Adjusted EBITDA margin was 24.9%, an increase of 2.1% vs. prior year.
•Company liquidity totaled $64.1 million, as of September 30, 2026.
Management Discussion
Carrie Lachance, Chief Executive Officer of InfuSystem commented, "We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform."
"Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment. These newer therapy categories continue to build on our established patient services infrastructure and reflect the success of our strategy to expand through manufacturer partnerships and complementary clinic-to-home therapies."
"The previously announced restructuring of our GE Healthcare contract continued to improve profitability during the quarter by reducing costs more than the related reduction in revenue. Combined with ongoing operational improvement initiatives across the business, these efforts contributed to higher margins, stronger earnings and improved cash generation. We also continued to
realize the benefits of our ERP implementation, with project-related expenses declining significantly from the prior year as we transitioned from implementation to ongoing optimization and stabilization activities."
"Based on our performance through the first nine months of the year, we are reaffirming our full-year guidance. After adjusting for the impact of the GE Healthcare contract restructuring, we continue to expect pro-forma revenue growth of 6% to 8% for 2026 and Adjusted EBITDA margins in the low-to-mid 20% range. We remain focused on disciplined execution, profitable growth and creating long-term value for our shareholders."
2026 Third Quarter Financial Review
Net revenues for the quarter ended September 30, 2026 (“2026 Third Quarter”) were $37.6 million, an increase of $1.1 million, or 3.0%, compared to $36.5 million for the quarter ended September 30, 2025 (“2025 Third Quarter”). The increase included higher net revenues for the Patient Services segment partially offset by lower net revenues for the Device Solutions segment. As we announced during our review of the 2025 third quarter, we restructured our largest biomedical services contract and, consequently, we started 2026 at a reduced revenue volume of $7.1 million for the full year including a $2.4 million reduction for the 2026 Third Quarter. This was a necessary change that has had an immediate favorable impact on our reported earnings and cash flows since we also achieved an even larger reduction in our expenses. After adjusting for this decreas
Aug 4, 2026 · 100% conf.
1D
+2.66%
$12.65
Act: -1.38%
5D
+13.22%
$13.95
20D
+16.39%
$14.34
2 infu-20260630xexx991earnin.htm
Document
Exhibit 99.1
InfuSystem Holdings, Inc.
3851 W. Hamlin Road
Rochester Hills, MI 48309
(248) 291-1210
Contact:
Barry Steele
Chief Financial Officer
(248) 260-2211
InfuSystem Announces Financial Results for
Second Quarter 2026
Net Revenues of $36.9 million Representing a 2.6% Increase from the Prior Year
Net income of $3.2 million
Adjusted EBITDA (non-GAAP) of $8.6 million
Adjusted EBITDA (non-GAAP) margin expanded by 1% to 23%
Reaffirms Full-Year 2026 Guidance
Rochester Hills, Michigan, August 4, 2026 – InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2026.
2026 Second Quarter Overview:
•Net revenues totaled $36.9 million, an increase of 2.6% vs. prior year.
◦Patient Services net revenue was $24.8 million, an increase of 15% vs. prior year.
◦Device Solutions net revenue was $12.1 million, a decrease of 16% vs. prior year.
•Gross profit was $21.4 million, an increase of 8% vs. prior year.
•Gross margin was 58%, an increase of 3% vs. prior year.
•Net income was $3.2 million, or $0.15 per diluted share vs. prior year net income of $2.6 million, or $0.12 per diluted share.
•Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) (non-GAAP) was $8.6 million, an increase of 8% vs. prior year.
•Adjusted EBITDA margin was 23.4%, an increase of 1.1% vs. prior year.
•Stock Repurchases totaled $3.5 million for the quarter.
•Company liquidity totaled $55.2 million, as of June 30, 2026.
Management Discussion
Carrie Lachance, Chief Executive Officer of InfuSystem commented, "We delivered another strong quarter, achieving record revenue of $36.9 million and growing Adjusted EBITDA by 7.6%. Our Oncology business continued its steady momentum, surpassing $20 million in quarterly revenue for the first time, while Wound Care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings. As our business continues to diversify, we remain focused on pursuing profitable growth while driving ever greater efficiencies."
"The previously reported restructuring of our GE Healthcare contract reduced reported revenue in our Device Solutions business unit, but it also improved the Company’s profitability through a greater reduction in direct costs. This has resulted in margin expansion and higher reported profits. The rapid growth of our compression therapy business has provided new revenue resources and we believe our payer network, operational capabilities, and manufacturer partnerships position us well for continued expansion. Behind the scenes, we made meaningful progress optimizing our new ERP platform, laying the foundation for greater scalability, efficiency, and long-term productivity improvements across the organization."
"Looking ahead, we remain focused on disciplined execution, delivering 6% to 8% pro forma revenue growth in 2026, maintaining strong EBITDA margins, and creating long-term value for our shareholders." concluded Ms. Lachance
2026 Second Quarter Financial Review
Net revenues for the quarter ended June 30, 2026 (“2026 Second Quarter”) were $36.9 million, an increase of $0.9 million, or 2.6%, compared to $36.0 million for the quarter ended June 30, 2025 (“2025 Second Quarter”). The increase included higher net revenues for the Patient Services segment partially offset by lower net revenues for the Device Solutions segment. As we announced during our review of the 2025 third quarter, we restructured our largest biomedical services contract and, consequently, we started 2026 at a reduced revenue volume of $1.6 million for the 2026 Second Quarter and $7.1 million for the full year. This was a necessary change that has had an immediate favorable impact on our reported earnings and cash flows since we also achieved an even larger reduction in our expenses. After adjusting for this decrease, our pro-forma growth rate was 7.5% during the 2026 Second Quarter as compared with the prior year period.
Patient Services net revenue of $24.8 million increased $3.3 million, or 15.2%, during the Second Quarter of 2026 compared to the prior year period. This increase was primarily attributable to additional treatment volume and increased third-party payer collections in Oncology and Wound Care. The improved volume and collections benefited Oncology revenue by $1.2 million, or 6.4% and Wound Care by $2.1 million, or 154%. The Wound Care net revenues included sales of Pneumatic Compression Devices (PCDs) and Adjustable Compression Wraps (ACW’s) stemming from two new supplier relationships. There was no PCD or ACW revenue in the second quarter of 2025 because the new products launched during the third quarter o
May 7, 2026 · 100% conf.
1D
-1.35%
$8.77
Act: -5.06%
5D
-8.76%
$8.11
Act: -3.15%
20D
-10.57%
$7.95
Act: +3.94%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784334117.ccd60770
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how INFU stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "INFU InfuSystems Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.